Karakaş, N. Et Al. 2023. Immunoreactivity against SLC3A2 in high grade gliomas displays positive correlation with glioblastoma patient survival: Potential target for glioma diagnosis and therapy. Biorxiv , vol.26 , 525653.

Karakaş, N., Topçu, O., Tüzün, E., Timirci Kahraman, Ö., Sabancı, P. A., Aras, Y., ... Yetimler, B.(2023). Immunoreactivity against SLC3A2 in high grade gliomas displays positive correlation with glioblastoma patient survival: Potential target for glioma diagnosis and therapy. Biorxiv , vol.26, 525653.

Karakaş, Nihal Et Al. "Immunoreactivity against SLC3A2 in high grade gliomas displays positive correlation with glioblastoma patient survival: Potential target for glioma diagnosis and therapy," Biorxiv , vol.26, 525653, 2023

Karakaş, Nihal Et Al. "Immunoreactivity against SLC3A2 in high grade gliomas displays positive correlation with glioblastoma patient survival: Potential target for glioma diagnosis and therapy." Biorxiv , vol.26, pp.525653, 2023

Karakaş, N. Et Al. (2023) . "Immunoreactivity against SLC3A2 in high grade gliomas displays positive correlation with glioblastoma patient survival: Potential target for glioma diagnosis and therapy." Biorxiv , vol.26, p.525653.

@article{article, author={Nihal Karakaş Et Al. }, title={Immunoreactivity against SLC3A2 in high grade gliomas displays positive correlation with glioblastoma patient survival: Potential target for glioma diagnosis and therapy}, journal={Biorxiv}, year=2023, pages={525653} }